PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8318063-6	1993	Postheparin lipoprotein lipase (LPL) and hepatic lipase (HL) activities were increased by gemfibrozil therapy while only a mild elevation in LPL activity alone was seen on lovastatin therapy.	Gemfibrozil	90-101	lipase C, hepatic type	Homo sapiens	41-55	
7595182-9	1995	Gemfibrozil increased LPL and HL activities by 18.2% (P < 0.05) and by 19.6%, respectively.	Gemfibrozil	0-11	lipase C, hepatic type	Homo sapiens	30-32	
7595182-11	1995	CONCLUSION: The gemfibrozil-induced elevation of HDL3 and apoA-II may reflect the combined action of LPL, HL and CETP on plasma HDL metabolism.	Gemfibrozil	16-27	lipase C, hepatic type	Homo sapiens	106-108	
8257455-11	1993	Gemfibrozil increased LPL and HL activities by 14.7% (P < 0.05) and by 18.8% (P < 0.01), respectively, while in the placebo group LPL and HL activities remained unchanged.	Gemfibrozil	0-11	lipase C, hepatic type	Homo sapiens	30-32	
8257455-14	1993	The gemfibrozil-induced elevation of HDL3 and dense HDL subpopulations may reflect the concerted action of LPL, HL and CETP on plasma HDL metabolism.	Gemfibrozil	4-15	lipase C, hepatic type	Homo sapiens	112-114	
190608-9	1976	The postheparin plasma lipoprotein lipase and hepatic lipase activities, determined separately by an immunochemical method, increased during four weeks of gemfibrozil treatment (+18.1% and +20.6% respectively), but neither of these changes was significantly correlated with the changes in any of the serum lipid or lipoprotein levels.	Gemfibrozil	155-166	lipase C, hepatic type	Homo sapiens	46-60	
3555908-0	1987	Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure.	Gemfibrozil	58-69	lipase C, hepatic type	Homo sapiens	40-54